The observed radio-sensitization in BRAF- and NRAS-mutant melanoma cells lines treated with TRT and MEKi combination will need, in the future, to be assessed by in vivo studies using human BRAF- and NRAS-mutant melanoma xenografts. This evidence concerns the gene BRAF and melanoma.